Bone Biologics completes $5M+ financing round: 3 things to know

Written by Anuja Vaidya | April 26, 2016 | Print  |

Bone Biologics completed a $5.75 million funding round.

Here are three things to know:


1. The funds will be used for the development and synthesis of a potential bone graft substitute product focused on bone regeneration in spinal fusion procedures.


2. The lead product, Nell-1, has shown clinical potential in the laboratory and in animal testing.


3. The funding round included Musculoskeletal Transplant Foundation, Orthofix and Hankey Capital.


More articles on devices:
Stryker's net earnings up 79.5%; Orthopedics sales reach $1.1B: 9 key notes on Q1 2016
FDA clears Exatech's Vantage Total Ankle — 5 highlights
Medtech's ROSA system to be featured at AANS annual meeting — 3 quick notes

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers